首站-论文投稿智能助手
典型文献
Role of adjuvant chemoradiotherapy and chemotherapy in patients with resected gallbladder carcinoma: a multi-institutional analysis (KROG 19-04)
文献摘要:
Objective: The effectiveness of adjuvant treatments for resected gallbladder carcinoma (GBC) has remained unclear due to lack of randomized controlled trials; thus, the aim of present study was to evaluate the role of adjuvant treatments, including chemoradiotherapy (CRT) and/or chemotherapy (CTx), in patients with resected GBC.Methods: A total of 733 GBC patients who received curative-intent surgical resection were identified in a multi-institutional database. Of 733 patients, 372 (50.8%) did not receive adjuvant treatment, whereas 215 (29.3%) and 146 (19.9%) received adjuvant CTx and CRT, respectively. The locoregional recurrence-free survival (LRFS), recurrence-free survival (RFS), and overall survival (OS) of the adjuvant treatment groups were compared according to tumor stage (stage Ⅱ vs. stage Ⅲ–IV). Results: In stage Ⅱ disease (n = 381), the 5-year LRFS, RFS, and OS were not significantly different among the no-adjuvant therapy, CTx, and CRT groups, and positive resection margin, presence of perineural invasion, and Nx classification were consistently associated with worse LRFS, RFS, and OS in the multivariate analysis (P < 0.05). For stage Ⅲ–IV (n = 352), the CRT group had significantly higher 5-year LRFS, RFS, and OS than the no-adjuvant therapy and CTx groups (67.8%, 45.2%, and 56.9%; 37.9%, 28.8%, and 35.4%; and 45.0%, 30.0%, and 45.7%, respectively) (P < 0.05). Conclusions: CRT has value as adjuvant treatment for resected GBC with stage Ⅲ–IV disease. Further study is needed for stage Ⅱ disease with high-risk features.
文献关键词:
作者姓名:
Sung Uk Lee;Jinsil Seong;Tae Hyun Kim;Jung Ho Im;Woo Chul Kim;Kyubo Kim;Hae Jin Park;Tae Gyu Kim;Youngkyong Kim;Bae Kwon Jeong;Jin Hee Kim;Byoung Hyuck Kim;Taek-Keun Nam
作者机构:
Center for Proton Therapy and Center for Liver and Pancreatobiliary Cancer,National Cancer Center,Goyang 10408,Korea;Department of Radiation Oncology,Yonsei Cancer Center,Yonsei University College of Medicine,Seoul 03722,Korea;Department of Radiation Oncology,CHA Bundang Medical Center,CHA University School of Medicine,Seongnam 13497,Korea;Department of Radiation Oncology,Inha University Hospital,Inha University School of Medicine,Incheon 22332,Korea;Department of Radiation Oncology,Ewha Womans University Mokdong Hospital,Ewha Womans University College of Medicine,Seoul 07985,Korea;Department of Radiation Oncology,Hanyang University Medical Center,Hanyang University College of Medicine,Seoul 04763,Korea;Department of Radiation Oncology,Samsung Changwon Hospital,Sungkyunkwan University School of Medicine,Changwon 51353,Korea;Department of Radiation Oncology,Kyung Hee University Hospital,Kyung Hee University College of Medicine,Seoul 02447,Korea;Department of Radiation Oncology,Gyeongsang National University Hospital,Gyeongsang National University College of Medicine,Jinju 52727,Korea;0Department of Radiation Oncology,Dongsan Medical Center,Keimyung University School of Medicine,Daegu 41931,Korea;1Department of Radiation Oncology,Seoul Metropolitan Government Seoul National University Boramae Medical Center,Seoul 07061,Korea;2Department of Radiation Oncology,Chonnam National University Hwasun Hospital,Chonnam National University College of Medicine,Hwasun 58128,Korea
引用格式:
[1]Sung Uk Lee;Jinsil Seong;Tae Hyun Kim;Jung Ho Im;Woo Chul Kim;Kyubo Kim;Hae Jin Park;Tae Gyu Kim;Youngkyong Kim;Bae Kwon Jeong;Jin Hee Kim;Byoung Hyuck Kim;Taek-Keun Nam-.Role of adjuvant chemoradiotherapy and chemotherapy in patients with resected gallbladder carcinoma: a multi-institutional analysis (KROG 19-04))[J].癌症生物学与医学(英文版),2022(06):931-944
A类:
KROG
B类:
Role,adjuvant,chemoradiotherapy,chemotherapy,patients,resected,gallbladder,carcinoma,institutional,analysis,Objective,effectiveness,treatments,GBC,has,remained,unclear,due,lack,randomized,controlled,trials,thus,aim,present,study,was,evaluate,role,including,CRT,CTx,Methods,total,who,received,curative,intent,surgical,resection,were,identified,database,Of,did,not,whereas,respectively,locoregional,recurrence,free,survival,LRFS,overall,OS,groups,compared,according,tumor,stage,IV,Results,In,disease,year,significantly,different,among,positive,margin,presence,perineural,invasion,Nx,classification,consistently,associated,worse,multivariate,For,had,higher,than,Conclusions,value,Further,needed,risk,features
AB值:
0.452178
相似文献
Prognostic nomogram incorporating radiological features for predicting overall survival in patients with AIDS-related non-Hodgkin lymphoma
Li Xueqin;Pan Ziang;Wang Xing;Hu Tianli;Ye Wen;Jiang Dongmei;Shen Wen;Liu Jinxin;Shi Yuxin;Xia Shuang;Li Hongjun-Radiological Department, Beijing You'an Hospital Affiliated of Capital Medical University, Beijing 100069, China;Neurological Department, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China;Radiological Department, The Eighth People's Hospital of Guangzhou, Guangzhou, Guangdong 510060, China;Radiological Department, Shanghai Public Health Clinical Center, Affiliated of Fudan University, Shanghai 201058, China;Radiation Department, Tianjin First Central Hospital, Tianjin 300170, China;Radiological Department, Tianjin First Central Hospital, Tianjin 300192, China
Tenofovir vs. entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma beyond Milan criteria after hepatectomy
Shen Junyi;Qi Weili;Dai Junlong;Leng Shusheng;Jiang Kangyi;Zhang Yu;Ran Shun;Li Chuan;Wen Tianfu-Department of Liver Surgery and Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China;Laboratory of Liver Transplantation, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China;Institute of Clinical Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China;Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of Chengdu University, Chengdu, Sichuan 610072, China;Department of Hepatobiliary and Pancreatic Surgery, The People's Hospital of Leshan, Leshan, Sichuan 614700, China;Department of Hepatobiliary Surgery, Sichuan Provincial People's Hospital, Chinese Academy of Sciences, Chengdu, Sichuan 610072, China;Department of Hepatobiliary Surgery, Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, Guizhou 550000, China
Hepatopancreatoduodenectomy for advanced biliary malignancies
Wu Xiangsong;Li Maolan;Wu Wenguang;Wang Xu’an;Li Huaifeng;Bao Runfa;Shu Yijun;Shen Jun;Gu Jun;Wang Xuefeng;Gong Wei;Peng Shuyou;Liu Yingbin-Department of General Surgery, Xinhua Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China;Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai 200092, China;Shanghai Research Center of Biliary Tract Disease, Shanghai 200092, China;Department of Biliary-Pancreatic Surgery, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China;State Key Laboratory of Oncogenes and Related Genes, Shanghai 200092, China;Department of General Surgery, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejing 310009, China
An international multicentric phase Ⅲ randomized controlled trial of time-acupoints-space acupuncture for the prevention of chemotherapy-induced fatigue in patients with early stage breast cancer:a study protocol
Saghachian Mahasti;Barry Caroline;Asselain Bernard;LI Yunfen;NIE Jianyun;LIU Dequan;CHEN Dedian;CHEN Chunxin;Laura Estevez;LI Wenhui;Jean-Pierre Armand;ZHU Miansheng;JU Liya-Institute Gustave Roussy,Paris,France;Research Center of Epidemiology and public health,Paris,France;Institute Curie of Paris,Paris,France;Yunnan Cancer Hospital,Third Affiliated Hospital of Kunming Medical University,Kunming,China;PreciMed Platform Europe,Paris,France,,MD Anderson Cancer Hospital,Madrid,Spain;ARIATAS Association pour la Recherche et l'Information de l'Acupuncture Time-Acupoints-Space,Paris,France
Clinical value of next-generation sequencing in guiding decisions regarding endocrine therapy for advanced HR-positive/HER-2-negative breast cancer
Dan Lyu;Binliang Liu;Bo Lan;Xiaoying Sun;Lixi Li;Jingtong Zhai;Haili Qian;Fei Ma-Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Department of Breast Cancer Medical Oncology,Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine,Central South University,Changsha 410013,China;Department of Medical Oncology,Cancer Hospital of Huanxing Chaoyang District,Beijing 100122,China;State Key Laboratory of Molecular Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China
Clinical outcomes of atezolizumab in combination with etoposide/platinum for treatment of extensive-stage small-cell lung cancer:A real-world,multicenter,retrospective,controlled study in China
Hanxiao Chen;Xiangjuan Ma;Jie Liu;Yu Yang;Yong Fang;Liping Wang;Jian Fang;Jun Zhao;Minglei Zhuo-Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department Ⅰ of Thoracic Oncology,Peking University Cancer Hospital&Institute,Beijing 100142,China;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department Ⅱ of Thoracic Oncology,Peking University Cancer Hospital&Institute,Beijing 100142,China;Department of Pneumology,Shandong Cancer Hospital and Institute,Shandong First Medical University and Shandong Academy of Medical Sciences,Jinan 250117,China;Department of Oncology,the 2nd Affiliated Hospital of Harbin Medical University,Harbin 150001,China;Department of Oncology,Sir Run Run Shaw Hospital Zhejiang University School of Medicine,Hangzhou 310020,China;Department of Oncology,Baotou Cancer Hospital,Baotou 014030,China
Predictors of pathologic complete response in patients with residual flat mucosal lesions after neoadjuvant chemoradiotherapy for locally advanced rectal cancer
Changlong Li;Zhen Guan;Yi Zhao;Tingting Sun;Zhongwu Li;Weihu Wang;Zhexuan Li;Lin Wang;Aiwen Wu-Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Gastrointestinal Cancer Center,Peking University Cancer Hospital&Institute,Beijing 100142,China;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Radiology,Peking University Cancer Hospital&Institute,Beijing 100142,China;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Pathology,Peking University Cancer Hospital&Institute,Beijing 100142,China;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Radiation Oncology,Peking University Cancer Hospital&Institute,Beijing 100142,China;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Cancer Epidemiology,Peking University Cancer Hospital&Institute,Beijing 100142,China
Adjuvant tamoxifen switched to exemestane treatment in postmenopausal women with estrogen receptor-positive early breast cancer: A pragmatic, multicenter, and prospective clinical trial in China
Binghe Xu;Huiping Li;Zefei Jiang;Lin Gu;Jinhai Tang;Hui Xie;Yueyin Pan;Yunjiang Liu;Shude Cui;Xiaojia Wang;Li Cai;Yiqiong Zhang;Huadong Zhao;Zhimin Shao-Department of Medical Oncology,National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Breast Oncology,Peking University Cancer Hospital&Institute,Beijing 100142,China;Department of Breast Cancer,the Fifth Medical Center of Chinese PLA General Hospital,Beijing 100071,China;Department of Breast Cancer,Tianjin Cancer Institute and Hospital,Tianjin 300060,China;Department of Breast Cancer,Jiangsu Provincial Hospital,Nanjing 210029,China;Department of Breast Cancer,the First Affiliated Hospital of China University of Science and Technology,Hefei 230001,China;Department of Breast Cancer,the Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,China;Department of Breast Cancer,Henan Cancer Hospital,Zhengzhou 450008,China;Department of Breast Cancer,Zhejiang Cancer Hospital,Hangzhou 310012,China;Department of Breast Cancer,Harbin Medical University Cancer Hospital,Harbin 150081,China;Department of Clinical Development,Pfizer(China)R&D Co.Ltd,Shanghai 201203,China;Department of Statistics,Pfizer(China)R&D Co.Ltd,Shanghai 201203,China;Department of Breast Surgery,Shanghai Cancer Center/Cancer Institute,Shanghai Medical College,Fudan University,Shanghai 200032,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。